Plamotamab

Names

[ Name ]:
Plamotamab

Biological Activity

[Description]:

Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and resultes in tumor regression in vivo[1][2].

[Related Catalog]:

Research Areas >> Cancer

[In Vitro]

Plamotamab 在体外诱导人 PBMC 内源性 B 细胞的杀伤和内源性 CD8+ T 细胞的激活，EC50 值为 0.113 nM[2]。 Plamotamab 在体外诱导 T 细胞介导的对 Raji 肿瘤细胞的杀伤，EC50 值为 0.144 nM[2]。 Plamotamab 结合 CD3δ/ε、CD3+ T 细胞、CD4+ T 细胞、CD8+ T 细胞、B 细胞、Raji 细胞，EC50 分别为 2.1 nM、11.78 nM、10.12 nM、200.3 nM 和 134.8 nM[2]。

[In Vivo]

Plamotamab (0.17 mg/kg；腹腔注射) 在含有 Raji 异种移植物的人 PBMC 移植小鼠模型中引起肿瘤生长抑制[2]。 Plamotamab (0.3 mg/kg；腹腔注射) 导致食蟹猴中细胞因子释放，安全性有待提高[2]。

[References]

[1]. Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.

[2]. Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.